Live Webinar | Health Plan Payment and Reimbursement
Live Webinar | hfma:content/topic/behavioral_ethics
Sponsored Content | Cost Reduction

Cost Reduction Program Summary Report

Sponsored by Strata Decision Technology
Sponsored Content | Cost Reduction

Cost Reduction Program Summary Report

HFMA, with sponsorship from Strata Decision Technology, surveyed 185 healthcare finance, accounting and revenue cycle executives to understand cost reduction programs and how effective they are. The survey indicates that while 89% of healthcare organization have some type of cost reduction program in place, only 6% say their program is extremely effective.

Survey respondents select how they approach cost reduction programs and how effective they have been.

Read more about this research here. To learn more, download the key findings from the survey

Sign up for a free guest account and get access to five free articles every month.


Related Articles | Cost Reduction

Article | Financial Leadership

How healthcare organizations can defend against financial hazards in 2023

What are the most critical strategies to steer healthcare organizations in the direction of financial stability in the following year and beyond? A couple tips include reducing bad debt and accessing external benchmarks for supply pricing.

News | Healthcare Business Trends

Reeling hospital industry shouldn’t anticipate a turnaround anytime soon

Hospital industry experts say a financial turnaround is unlikely in subsequent months and beyond.

Article | Electronic Health Records

Most healthcare organizations want to augment current EHR workflows and would consider flexible outsourcing contracts

This pulse survey shows that there is no one-size-fits-all solution for managing today’s revenue cycle challenges. Savvy healthcare organizations know they need a combination of actionable insights and high-performance work teams to be successful.

Article | Cost Reduction

Why addressing unexplained variations in care should be a healthcare system priority

Healthcare researchers believe Medicare could save $2 billion by using a cheaper drug for retinal disease, but some physicians don’t want to switch.